{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:46:46Z","timestamp":1793375206422,"version":"4.5.0"},"reference-count":152,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiac disease and a leading cause of heart failure, arrhythmia, and sudden cardiac death in both young and older adults. This consensus document was developed by a multidisciplinary panel of European and U.S. experts in HCM, imaging, electrophysiology, genetics, and heart failure. While it aligns with the 2023 ESC and 2024 AHA\/ACC guidelines on HCM, the paper addresses areas where clinicians might require further guidance. Key sections include phenotypic classification, diagnostic strategies incorporating multimodal imaging and genetic testing, and risk stratification for sudden cardiac death. The document outlines therapeutic pathways for pharmacologic treatment, including beta-blockers, calcium channel blockers, disopyramide, and cardiac myosin inhibitors such as mavacamten and aficamten, as well as indications for septal reduction therapies. Management of atrial fibrillation, hypertension, coronary artery disease, pregnancy, paediatric HCM, and comorbidities is discussed in detail. Importantly, the consensus addresses current controversies including optimal risk stratification models, the care of genotype-positive\/phenotype-negative individuals, and exercise recommendations. Finally, the manuscript highlights future directions such as gene therapy, precision medicine approaches, use of artificial intelligence and novel biomarkers for screening and diagnosis.<\/jats:p>","DOI":"10.1093\/ejhf\/xuaf008","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:25:47Z","timestamp":1767702347000},"page":"299-314","source":"Crossref","is-referenced-by-count":9,"title":["EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0741-2633","authenticated-orcid":false,"given":"Benjamin","family":"Meder","sequence":"first","affiliation":[{"name":"Department of Cardiology, Angiology and Pulmonology, Institut f\u00fcr Cardiomyopathien Heidelberg, University of Heidelberg, INF 410 , Im Neuenheimer Feld 410, Heidelberg 69120 ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK) Partnerside Heidelberg , Heidelberg ,","place":["Germany"]},{"name":"Precision Digital Health and Informatics for Life, Department of Cardiology, Angiology and Pulmonology, University of Heidelberg , Im Neuenheimer Feld 410, Heidelberg 69120 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J","family":"Coats","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A","family":"Leinwand","sequence":"additional","affiliation":[{"name":"BioFrontiers Institute, University of Colorado at Boulder , Boulder, CO ,","place":["USA"]},{"name":"Molecular, Cellular, and Developmental Biology, University of Colorado at Boulder , Boulder, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital , Florence ,","place":["Italy"]},{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5470-2257","authenticated-orcid":false,"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV , Manuel de Falla, 2, Madrid 28222 ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0010-9797","authenticated-orcid":false,"given":"Milind Y","family":"Desai","sequence":"additional","affiliation":[{"name":"Hypertrophic Cardiomyopathy Center , Cleveland, OH ,","place":["USA"]},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Heart, Vascular and Thoracic Institute, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farbod","family":"Sedaghat-Hamedani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology and Pulmonology, Institut f\u00fcr Cardiomyopathien Heidelberg, University of Heidelberg, INF 410 , Im Neuenheimer Feld 410, Heidelberg 69120 ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK) Partnerside Heidelberg , Heidelberg ,","place":["Germany"]},{"name":"Precision Digital Health and Informatics for Life, Department of Cardiology, Angiology and Pulmonology, University of Heidelberg , Im Neuenheimer Feld 410, Heidelberg 69120 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026051117352551900_xuaf008-B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijcard.2023.04.005","article-title":"How common is hypertrophic cardiomyopathy\u2026 really?: disease prevalence revisited 27 years after CARDIA","volume":"382","author":"Massera","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026051117352551900_xuaf008-B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00392-017-1155-5","article-title":"Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals","volume":"107","author":"Sedaghat-Hamedani","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2026051117352551900_xuaf008-B3","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.37765\/ajmc.2021.88628","article-title":"Hypertrophic cardiomyopathy: diagnosis and therapeutic options","volume":"27","author":"Gluckman","year":"2021","journal-title":"Am J Manag Care"},{"key":"2026051117352551900_xuaf008-B4","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/CIR.0000000000000937","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B5","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B6","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026051117352551900_xuaf008-B8","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.amjmed.2016.09.015","article-title":"Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored \u2026 until now","volume":"130","author":"Maron","year":"2017","journal-title":"Am J Med"},{"key":"2026051117352551900_xuaf008-B10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B11","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B12","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.amjcard.2023.10.073","article-title":"Advances in the management of hypertrophic cardiomyopathy leading to low disease-related mortality in 2023","volume":"212s","author":"Maron","year":"2024","journal-title":"Am J Cardiol"},{"key":"2026051117352551900_xuaf008-B13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","article-title":"Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy","volume":"348","author":"Maron","year":"2003","journal-title":"N Engl J Med"},{"key":"2026051117352551900_xuaf008-B14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1161\/CIRCRESAHA.116.309348","article-title":"Hypertrophic obstructive cardiomyopathy: surgical myectomy and septal ablation","volume":"121","author":"Nishimura","year":"2017","journal-title":"Circ Res"},{"key":"2026051117352551900_xuaf008-B15","doi-asserted-by":"publisher","first-page":"e006657","DOI":"10.1161\/JAHA.117.006657","article-title":"Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy","volume":"7","author":"Lu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026051117352551900_xuaf008-B16","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1161\/CIR.0b013e318223e2bd","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B17","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1093\/eurheartj\/ehaf026","article-title":"Hypertrophic cardiomyopathy: prevalence of disease-specific red flags","volume":"46","author":"Maurizi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B18","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Authors\/Task Force members","year":"2014","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B19","doi-asserted-by":"publisher","first-page":"1252266","DOI":"10.3389\/fcvm.2023.1252266","article-title":"A systematic review and meta-analysis of sex differences in clinical outcomes of hypertrophic cardiomyopathy","volume":"10","author":"Liu","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026051117352551900_xuaf008-B20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jcmg.2023.07.012","article-title":"Improved diagnostic criteria for apical hypertrophic cardiomyopathy","volume":"17","author":"Hughes","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026051117352551900_xuaf008-B21","doi-asserted-by":"publisher","first-page":"101531","DOI":"10.1016\/j.jacadv.2024.101531","article-title":"Goal-directed versus self-directed valsalva maneuver in patients with hypertrophic cardiomyopathy on cardiac myosin inhibitor therapy","volume":"4","author":"Bavishi","year":"2025","journal-title":"JACC Adv"},{"key":"2026051117352551900_xuaf008-B22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.echo.2018.01.022","article-title":"Standardized goal-directed valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy","volume":"31","author":"Kumar","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"key":"2026051117352551900_xuaf008-B23","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/echo.12951","article-title":"Postprandial hemodynamics in hypertrophic cardiomyopathy","volume":"32","author":"Adams","year":"2015","journal-title":"Echocardiography"},{"key":"2026051117352551900_xuaf008-B24","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jcmg.2017.07.016","article-title":"Role of exercise testing in hypertrophic cardiomyopathy","volume":"10","author":"Rowin","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026051117352551900_xuaf008-B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/ehjci\/jew313","article-title":"Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study","volume":"19","author":"Reant","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026051117352551900_xuaf008-B26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.amjcard.2023.11.003","article-title":"Prognostic role of the progression of late gadolinium enhancement in hypertrophic cardiomyopathy","volume":"211","author":"Aquaro","year":"2024","journal-title":"Am J Cardiol"},{"key":"2026051117352551900_xuaf008-B27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B28","doi-asserted-by":"publisher","first-page":"e003285","DOI":"10.1161\/CIRCIMAGING.115.003285","article-title":"T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study","volume":"8","author":"Hinojar","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026051117352551900_xuaf008-B29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ahj.2015.05.013","article-title":"Hypertrophic cardiomyopathy registry: the rationale and design of an international, observational study of hypertrophic cardiomyopathy","volume":"170","author":"Kramer","year":"2015","journal-title":"Am Heart J"},{"key":"2026051117352551900_xuaf008-B30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/cvr\/cvv025","article-title":"Genetic advances in sarcomeric cardiomyopathies: state of the art","volume":"105","author":"Ho","year":"2015","journal-title":"Cardiovasc Res"},{"key":"2026051117352551900_xuaf008-B31","doi-asserted-by":"publisher","first-page":"102236","DOI":"10.1016\/j.jaccas.2024.102236","article-title":"ATTR gene variants in HCM","volume":"29","author":"Kanelidis","year":"2024","journal-title":"JACC Case Rep"},{"key":"2026051117352551900_xuaf008-B32","doi-asserted-by":"publisher","first-page":"e002930","DOI":"10.1161\/CIRCGEN.120.002930","article-title":"Revisiting the diagnostic yield of hypertrophic cardiomyopathy genetic testing","volume":"13","author":"Butters","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"2026051117352551900_xuaf008-B33","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/genes16091100","article-title":"Genetic, clinical, and sociodemographic profile in individuals with diagnosis or family history of hypertrophic cardiomyopathy: insights from a prospective cohort","volume":"16","author":"Santos","year":"2025","journal-title":"Genes (Basel)"},{"key":"2026051117352551900_xuaf008-B34","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"2026051117352551900_xuaf008-B35","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00392-023-02310-4","article-title":"Improving sudden cardiac death risk stratification in hypertrophic cardiomyopathy using established clinical variables and genetic information","volume":"113","author":"Amr","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026051117352551900_xuaf008-B36","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.hrthm.2024.09.040","article-title":"Extended ambulatory ECG monitoring enhances identification of higher-risk ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy","volume":"22","author":"Rowin","year":"2025","journal-title":"Heart Rhythm"},{"key":"2026051117352551900_xuaf008-B37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40138-022-00248-x","article-title":"The use of wearable ECG devices in the clinical setting: a review","volume":"10","author":"Kamga","year":"2022","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"2026051117352551900_xuaf008-B38","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1161\/01.CIR.0000097110.55312.BF","article-title":"Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease","volume":"108","author":"Sorajja","year":"2003","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0735-1097(03)00854-4","article-title":"Myocardial bridging in adult patients with hypertrophic cardiomyopathy","volume":"42","author":"Sorajja","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12968-020-00623-1","article-title":"Prevalence and clinical significance of cardiovascular magnetic resonance adenosine stress-induced myocardial perfusion defect in hypertrophic cardiomyopathy","volume":"22","author":"Kim","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026051117352551900_xuaf008-B41","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.106.657023","article-title":"Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging","volume":"115","author":"Petersen","year":"2007","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B42","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/ehjci\/jeac008","article-title":"Brockenbrough-Braunwald-Morrow sign and Valsalva manoeuvre: how to unmask dynamic left ventricular outflow tract obstruction","volume":"23","author":"Mabalukwa","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026051117352551900_xuaf008-B43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/0735-1097(92)90135-A","article-title":"Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making","volume":"20","author":"Grigg","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijcard.2022.09.036","article-title":"Does a standard myectomy exist for obstructive hypertrophic cardiomyopathy? From the Morrow variations to precision surgery","volume":"371","author":"Stefano","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026051117352551900_xuaf008-B45","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ijcard.2022.03.013","article-title":"Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study","volume":"354","author":"Monda","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026051117352551900_xuaf008-B47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1573403X1201160126125403","article-title":"Drug therapy for hypertrophic cardiomypathy: physiology and practice","volume":"12","author":"Sherrid","year":"2016","journal-title":"Curr Cardiol Rev"},{"key":"2026051117352551900_xuaf008-B48","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/hr.2016.101","article-title":"Comparison of bisoprolol to a metoprolol CR\/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study","volume":"40","author":"Yang","year":"2017","journal-title":"Hypertens Res"},{"key":"2026051117352551900_xuaf008-B49","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jchf.2024.11.011","article-title":"Aficamten vs metoprolol for obstructive hypertrophic cardiomyopathy: MAPLE-HCM rationale, study design, and baseline characteristics","volume":"13","author":"Garcia-Pavia","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026051117352551900_xuaf008-B50","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0002-9149(96)00336-0","article-title":"Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy","volume":"78","author":"Betocchi","year":"1996","journal-title":"Am J Cardiol"},{"key":"2026051117352551900_xuaf008-B51","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","article-title":"Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside","volume":"82","author":"Palandri","year":"2022","journal-title":"Drugs"},{"key":"2026051117352551900_xuaf008-B52","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1536\/ihj.27.701","article-title":"Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study","volume":"27","author":"Toshima","year":"1986","journal-title":"Jpn Heart J"},{"key":"2026051117352551900_xuaf008-B53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/01.CIR.64.3.437","article-title":"Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy","volume":"64","author":"Epstein","year":"1981","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B54","doi-asserted-by":"publisher","first-page":"ytae596","DOI":"10.1093\/ehjcr\/ytae596","article-title":"A case report of verapamil toxicity leading to haemodynamic compromise in obstructive hypertrophic cardiomyopathy","volume":"8","author":"Gau","year":"2024","journal-title":"Eur Heart J Case Rep"},{"key":"2026051117352551900_xuaf008-B55","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/hrt.52.1.106","article-title":"Detrimental effects of verapamil in patients with primary pulmonary hypertension","volume":"52","author":"Packer","year":"1984","journal-title":"Br Heart J"},{"key":"2026051117352551900_xuaf008-B56","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1378\/chest.105.2.606","article-title":"Noncardiogenic pulmonary edema complicating massive verapamil overdose","volume":"105","author":"Leesar","year":"1994","journal-title":"Chest"},{"key":"2026051117352551900_xuaf008-B57","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B58","doi-asserted-by":"publisher","first-page":"e005152","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of outpatient initiation of disopyramide for obstructive hypertrophic cardiomyopathy patients","volume":"6","author":"Adler","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026051117352551900_xuaf008-B59","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026051117352551900_xuaf008-B60","doi-asserted-by":"publisher","first-page":"e011188","DOI":"10.1161\/CIRCHEARTFAILURE.123.011188","article-title":"Long-term effects of mavacamten on electromechanical dispersion and deformation in obstructive hypertrophic cardiomyopathy","volume":"17","author":"Del Franco","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026051117352551900_xuaf008-B61","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026051117352551900_xuaf008-B62","doi-asserted-by":"publisher","first-page":"e035993","DOI":"10.1161\/JAHA.124.035993","article-title":"Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM","volume":"13","author":"Coats","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026051117352551900_xuaf008-B63","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051117352551900_xuaf008-B64","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"2026051117352551900_xuaf008-B65","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B66","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy: design, rationale, and baseline characteristics of ODYSSEY-HCM","volume":"13","author":"Desai","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026051117352551900_xuaf008-B67","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","article-title":"Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"key":"2026051117352551900_xuaf008-B68","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ejhf.3291","article-title":"Sacubitril\/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: an open label randomized controlled trial (SILICOFCM)","volume":"26","author":"Velicki","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051117352551900_xuaf008-B69","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cardfail.2024.10.419","article-title":"EDG-7500, a first-in-class cardiac sarcomere modulator, demonstrates favorable tolerability, safety, and pharmacokinetics in healthy adults","volume":"31","author":"Dufton","year":"2025","journal-title":"J Card Fail"},{"key":"2026051117352551900_xuaf008-B70","doi-asserted-by":"publisher","first-page":"A4142919","DOI":"10.1161\/circ.150.suppl_1.4142919","article-title":"Chronic administration of EDG-7500, a novel sarcomere modulator, prevents increases in cardiac mass, T1 relaxation time, and left ventricular end diastolic pressure in a Yucatan mini-pig model of genetic nonobstructive hypertrophic cardiomyopathy","volume":"150","author":"Emter","year":"2024","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B71","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","article-title":"Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy","volume":"83","author":"Maron","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B72","doi-asserted-by":"publisher","first-page":"9599","DOI":"10.3390\/ijms21249599","article-title":"Small molecules acting on myofilaments as treatments for heart and skeletal muscle diseases","volume":"21","author":"Alsulami","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026051117352551900_xuaf008-B73","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jacc.2009.09.047","article-title":"Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy","volume":"55","author":"Agarwal","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B74","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","article-title":"American College of Cardiology\/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines","volume":"42","author":"Maron","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B75","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/jcm12082810","article-title":"Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: a contemporary perspective","volume":"12","author":"Gragnano","year":"2023","journal-title":"J Clin Med"},{"key":"2026051117352551900_xuaf008-B76","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaccas.2019.11.053","article-title":"Two hearts at risk: emergency alcohol septal ablation in a pregnant woman with decompensated HOCM","volume":"2","author":"Gi","year":"2020","journal-title":"JACC Case Rep"},{"key":"2026051117352551900_xuaf008-B77","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/ccd.26293","article-title":"A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy","volume":"88","author":"Singh","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026051117352551900_xuaf008-B78","doi-asserted-by":"publisher","first-page":"268","DOI":"10.31083\/j.rcm2409268","article-title":"Septal myectomy and subvalvular repair in hypertrophic cardiomyopathy, a systematic review and pooled analysis","volume":"24","author":"Song","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"2026051117352551900_xuaf008-B79","doi-asserted-by":"publisher","first-page":"e018435","DOI":"10.1161\/JAHA.120.018435","article-title":"Outcomes in patients with obstructive hypertrophic cardiomyopathy and concomitant aortic stenosis undergoing surgical myectomy and aortic valve replacement","volume":"10","author":"Desai","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026051117352551900_xuaf008-B80","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.amjcard.2022.06.007","article-title":"Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC expert panel","volume":"180","author":"Maron","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026051117352551900_xuaf008-B81","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.amjcard.2019.07.031","article-title":"Comparison of effectiveness of alcohol septal ablation versus ventricular septal myectomy on acute care use for cardiovascular disease in patients with hypertrophic cardiomyopathy","volume":"124","author":"Shimada","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026051117352551900_xuaf008-B82","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.jacc.2015.07.069","article-title":"Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy","volume":"66","author":"Ferrazzi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B83","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.amjcard.2023.10.064","article-title":"Treatment strategies for hypertrophic cardiomyopathy: alcohol septal ablation and procedural step-by-step technique","volume":"212S","author":"Bali","year":"2024","journal-title":"Am J Cardiol"},{"key":"2026051117352551900_xuaf008-B84","doi-asserted-by":"publisher","first-page":"e007673","DOI":"10.1161\/CIRCINTERVENTIONS.118.007673","article-title":"Guideline-based referral for septal reduction therapy in obstructive hypertrophic cardiomyopathy is associated with excellent clinical outcomes","volume":"12","author":"Kimmelstiel","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"2026051117352551900_xuaf008-B85","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.107.738740","article-title":"Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"118","author":"Sorajja","year":"2008","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B86","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.jcin.2022.08.011","article-title":"New pacemaker implantation after alcohol septal ablation: how sharp is the double-edged sword?","volume":"15","author":"Pineda","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2026051117352551900_xuaf008-B87","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.124.069378","article-title":"Long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy: insights from the SHARE registry","volume":"150","author":"Maurizi","year":"2024","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B88","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.xjtc.2024.09.006","article-title":"An innovative minimally invasive approach for hypertrophic obstructive cardiomyopathy: transaortic septal myectomy via right infra-axillary incision","volume":"28","author":"Dong","year":"2024","journal-title":"JTCVS Tech"},{"key":"2026051117352551900_xuaf008-B89","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11748-018-0908-z","article-title":"Minimally invasive trans-mitral septal myectomy for diffuse-type hypertrophic obstructive cardiomyopathy","volume":"66","author":"Sakaguchi","year":"2018","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2026051117352551900_xuaf008-B90","doi-asserted-by":"publisher","first-page":"e003166","DOI":"10.1136\/openhrt-2025-003166","article-title":"Efficacy and safety of myectomy and radiofrequency septal ablation for treating hypertrophic obstructive cardiomyopathy","volume":"12","author":"Bruscky","year":"2025","journal-title":"Open Heart"},{"key":"2026051117352551900_xuaf008-B91","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/clc.23341","article-title":"Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis","volume":"43","author":"Yang","year":"2020","journal-title":"Clin Cardiol"},{"key":"2026051117352551900_xuaf008-B92","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1097\/MS9.0000000000002243","article-title":"Percutaneous endocardial septal radiofrequency ablation on syncope in patients with hypertrophic obstructive cardiomyopathy: a short-term safety and efficacy study","volume":"86","author":"Tian","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"2026051117352551900_xuaf008-B93","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.hroo.2023.01.002","article-title":"Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: a proportional meta-analysis and systematic review of single-arm studies","volume":"4","author":"Latif","year":"2023","journal-title":"Heart Rhythm O2"},{"key":"2026051117352551900_xuaf008-B94","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijcard.2023.04.008","article-title":"Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring","volume":"381","author":"Fumagalli","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026051117352551900_xuaf008-B95","doi-asserted-by":"publisher","first-page":"101210","DOI":"10.1016\/j.jacadv.2024.101210","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy","volume":"3","author":"Weissler-Snir","year":"2024","journal-title":"JACC Adv"},{"key":"2026051117352551900_xuaf008-B96","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s43856-023-00315-8","article-title":"Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy","volume":"3","author":"Chen","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"2026051117352551900_xuaf008-B97","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMoa2509542","article-title":"Increasing the potassium level in patients at high risk for ventricular arrhythmias","volume":"393","author":"Jons","year":"2025","journal-title":"N Engl J Med"},{"key":"2026051117352551900_xuaf008-B98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2023.10.008","article-title":"The current best drug treatment for hypertensive heart failure with preserved ejection fraction","volume":"120","author":"Rist","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026051117352551900_xuaf008-B99","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","article-title":"Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology\/European Society of Hypertension Guidelines","volume":"79","author":"Mancia","year":"2022","journal-title":"Hypertension"},{"key":"2026051117352551900_xuaf008-B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajh\/hpad073","article-title":"What is the current best drug treatment for hypertensive heart failure with preserved ejection fraction? Review of the totality of evidence","volume":"37","author":"Sevre","year":"2024","journal-title":"Am J Hypertens"},{"key":"2026051117352551900_xuaf008-B101","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026051117352551900_xuaf008-B102","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jchf.2023.07.030","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy with or without hypertension: post-hoc analysis of the EXPLORER-HCM trial","volume":"12","author":"Wang","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026051117352551900_xuaf008-B103","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jacc.2021.07.042","article-title":"Coronary microvascular dysfunction across the spectrum of cardiovascular diseases: JACC state-of-the-art review","volume":"78","author":"Del Buono","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B104","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B105","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/ehjcvp\/pvu020","article-title":"Pharmacotherapy for coronary microvascular dysfunction","volume":"1","author":"Ong","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026051117352551900_xuaf008-B106","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across Various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B107","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051117352551900_xuaf008-B108","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B109","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051117352551900_xuaf008-B110","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.cardfail.2024.08.026","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of SOtaglifloziN in patients with SymptomATic obstructive and non-obstructive hypertrophic CardioMyopathy (SONATA-HCM)","volume":"30","author":"Ho","year":"2024","journal-title":"J Card Fail"},{"key":"2026051117352551900_xuaf008-B111","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12872-024-03812-3","article-title":"Pregnancy related complications in women with hypertrophic cardiomyopathy: a nationwide population-based cohort study","volume":"24","author":"Choi","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"2026051117352551900_xuaf008-B112","doi-asserted-by":"publisher","first-page":"e884","DOI":"10.1161\/CIR.0000000000000772","article-title":"Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association","volume":"141","author":"Mehta","year":"2020","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B113","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/eurheartj\/ehx189","article-title":"Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC)","volume":"38","author":"Goland","year":"2017","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B114","doi-asserted-by":"publisher","first-page":"102057","DOI":"10.1016\/j.jaccas.2023.102057","article-title":"Multidisciplinary approach to management of hypertrophic cardiomyopathy with severe left ventricular outflow obstruction in pregnancy","volume":"27","author":"Bhave","year":"2023","journal-title":"JACC Case Rep"},{"key":"2026051117352551900_xuaf008-B115","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/S0735-1097(02)02495-6","article-title":"Risk associated with pregnancy in hypertrophic cardiomyopathy","volume":"40","author":"Autore","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B116","doi-asserted-by":"publisher","first-page":"e2138071","DOI":"10.1001\/jamanetworkopen.2021.38071","article-title":"Adverse pregnancy outcomes and incident heart failure in the women's health initiative","volume":"4","author":"Hansen","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026051117352551900_xuaf008-B117","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1093\/eurheartj\/ehaf193","article-title":"2025 ESC guidelines for the management of cardiovascular disease and pregnancy","volume":"46","author":"De Backer","year":"2025","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B118","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40119-024-00351-y","article-title":"Contemporary management of cardiomyopathy and heart failure in pregnancy","volume":"13","author":"Afari","year":"2024","journal-title":"Cardiol Ther"},{"key":"2026051117352551900_xuaf008-B119","doi-asserted-by":"publisher","first-page":"e44043","DOI":"10.7759\/cureus.44043","article-title":"Beta-blockers and their current role in maternal and neonatal health: a narrative review of the literature","volume":"15","author":"Martinez","year":"2023","journal-title":"Cureus"},{"key":"2026051117352551900_xuaf008-B120","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B121","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jccase.2017.12.009","article-title":"Successful alcohol septal ablation in a pregnant patient with symptomatic hypertrophic obstructive cardiomyopathy","volume":"17","author":"Shaikh","year":"2018","journal-title":"J Cardiol Cases"},{"key":"2026051117352551900_xuaf008-B122","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","article-title":"Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events","volume":"3","author":"Maurizi","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026051117352551900_xuaf008-B123","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B124","doi-asserted-by":"publisher","first-page":"e012932","DOI":"10.1161\/CIRCEP.124.012932","article-title":"Independent external evaluation of pediatric hypertrophic cardiomyopathy risk scores in predicting severe ventricular arrhythmias","volume":"18","author":"Wilkin","year":"2025","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026051117352551900_xuaf008-B125","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/eurjpc\/zwab181","article-title":"External validation of the HCM risk-kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"29","author":"Norrish","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026051117352551900_xuaf008-B126","doi-asserted-by":"publisher","first-page":"101520","DOI":"10.1016\/j.xcrm.2024.101520","article-title":"Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction","volume":"5","author":"Kinnear","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026051117352551900_xuaf008-B127","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1093\/eurheartj\/ehaf364","article-title":"Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUIOA-HCM trial","volume":"46","author":"Maron","year":"2025","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B128","doi-asserted-by":"publisher","first-page":"e012393","DOI":"10.1161\/CIRCHEARTFAILURE.124.012393","article-title":"Proteomic analysis of valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) clinical trial","volume":"18","author":"Topriceanu","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026051117352551900_xuaf008-B129","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/ejhf.3372","article-title":"Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: a 36-week analysis from FOREST-HCM","volume":"26","author":"Masri","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051117352551900_xuaf008-B130","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026051117352551900_xuaf008-B131","doi-asserted-by":"publisher","first-page":"132951","DOI":"10.1016\/j.ijcard.2024.132951","article-title":"Family screening for hypertrophic cardiomyopathy: initial cardiologic assessment, and long-term follow-up of genotype-positive phenotype-negative individuals","volume":"422","author":"Schoonvelde","year":"2025","journal-title":"Int J Cardiol"},{"key":"2026051117352551900_xuaf008-B132","doi-asserted-by":"publisher","first-page":"e036593","DOI":"10.1161\/JAHA.124.036593","article-title":"Cardiopulmonary fitness and personalized exercise prescription in patients with hypertrophic cardiomyopathy","volume":"13","author":"Cavigli","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026051117352551900_xuaf008-B133","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jacc.2022.07.013","article-title":"Athletic activity for patients with hypertrophic cardiomyopathy and other inherited cardiovascular diseases: JACC focus seminar 3\/4","volume":"80","author":"Semsarian","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B134","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/jamacardio.2023.1042","article-title":"Vigorous exercise in patients with hypertrophic cardiomyopathy","volume":"8","author":"Lampert","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026051117352551900_xuaf008-B135","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5837\/bjc.2020.011","article-title":"Hypertrophic cardiomyopathy and exercise restrictions: time to let the shackles off?","volume":"27","author":"Liao","year":"2020","journal-title":"Br J Cardiol"},{"key":"2026051117352551900_xuaf008-B136","doi-asserted-by":"publisher","first-page":"100922","DOI":"10.1016\/j.jacadv.2024.100922","article-title":"Precision medicine for all? : what about hypertrophic cardiomyopathy?","volume":"3","author":"Maron","year":"2024","journal-title":"JACC Adv"},{"key":"2026051117352551900_xuaf008-B137","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1093\/eurheartj\/ehy249","article-title":"CRISPR\/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy","volume":"39","author":"Mosqueira","year":"2018","journal-title":"Eur Heart J"},{"key":"2026051117352551900_xuaf008-B138","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41434-023-00384-3","article-title":"Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy","volume":"30","author":"Nie","year":"2023","journal-title":"Gene Ther"},{"key":"2026051117352551900_xuaf008-B139","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1161\/CIR.0000000000001296","article-title":"Gene therapy in cardiovascular disease: recent advances and future directions in science: a science advisory from the American Heart Association","volume":"150","author":"Kim","year":"2024","journal-title":"Circulation"},{"key":"2026051117352551900_xuaf008-B140","doi-asserted-by":"publisher","first-page":"e2200289","DOI":"10.1002\/pmic.202200289","article-title":"Multi-omic analyses and network biology in cardiovascular disease","volume":"23","author":"Reitz","year":"2023","journal-title":"Proteomics"},{"key":"2026051117352551900_xuaf008-B141","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ehjdh\/ztae029","article-title":"Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study","volume":"5","author":"Siontis","year":"2024","journal-title":"Eur Heart J Digit Health"},{"key":"2026051117352551900_xuaf008-B142","doi-asserted-by":"publisher","first-page":"100582","DOI":"10.1016\/j.jacadv.2023.100582","article-title":"Patient-level artificial intelligence-enhanced electrocardiography in hypertrophic cardiomyopathy: longitudinal treatment and clinical biomarker correlations","volume":"2","author":"Siontis","year":"2023","journal-title":"JACC Adv"},{"key":"2026051117352551900_xuaf008-B143","doi-asserted-by":"publisher","first-page":"103228","DOI":"10.1016\/j.jaccas.2024.103228","article-title":"Artificial intelligence-based electrocardiographic analysis facilitated diagnosis of hypertrophic cardiomyopathy with successful treatment using mavacamten","volume":"30","author":"Desai","year":"2025","journal-title":"JACC Case Rep"},{"key":"2026051117352551900_xuaf008-B144","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41591-024-02971-2","article-title":"Screening and diagnosis of cardiovascular disease using artificial intelligence-enabled cardiac magnetic resonance imaging","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"2026051117352551900_xuaf008-B145","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jacc.2019.12.030","article-title":"Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram","volume":"75","author":"Ko","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026051117352551900_xuaf008-B146","doi-asserted-by":"publisher","first-page":"e012667","DOI":"10.1161\/CIRCHEARTFAILURE.124.012667","article-title":"Detection of hypertrophic cardiomyopathy on electrocardiogram using artificial intelligence","volume":"18","author":"Hillis","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026051117352551900_xuaf008-B147","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacep.2025.02.024","article-title":"Real-world artificial intelligence-based electrocardiographic analysis to diagnose hypertrophic cardiomyopathy","volume":"11","author":"Desai","year":"2025","journal-title":"JACC Clin Electrophysiol"},{"key":"2026051117352551900_xuaf008-B148","doi-asserted-by":"publisher","first-page":"e53616","DOI":"10.2196\/53616","article-title":"Benefits and risks of AI in health care: narrative review","volume":"13","author":"Chustecki","year":"2024","journal-title":"Interact J Med Res"},{"key":"2026051117352551900_xuaf008-B149","doi-asserted-by":"publisher","first-page":"225","DOI":"10.31083\/j.rcm2506225","article-title":"Assessing the applicability of cardiac myosin inhibitors for hypertrophic cardiomyopathy management in a large single center cohort","volume":"25","author":"Amr","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"2026051117352551900_xuaf008-B150","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02544-w","article-title":"Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period","author":"Becker","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026051117352551900_xuaf008-B151","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City cardiomyopathy questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026051117352551900_xuaf008-B152","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1002\/ehf2.14345","article-title":"Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care","volume":"10","author":"Garmany","year":"2023","journal-title":"ESC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuaf008\/66271941\/xuaf008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/2\/299\/66271941\/xuaf008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/2\/299\/66271941\/xuaf008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:35:36Z","timestamp":1778535336000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/2\/299\/8415129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":152,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,5,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuaf008","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,8]]}}}